Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

The translational landscape of mTOR signalling steers cancer initiation and metastasis

(2012) Andrew C. Hsieh et al.   NATURE

Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks

(2011) Brian Magnuson et al.   BIOCHEMICAL JOURNAL

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

(2011) J. Hoellenriegel et al.   BLOOD

Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors

(2011) J. K. Altman et al.   CLINICAL CANCER RESEARCH

Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting

(2011) Marina Y. Konopleva et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia

(2011) C Evangelisti et al.   LEUKEMIA

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia

(2011) L Willems et al.   LEUKEMIA

The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies

(2011) Jan A. Burger et al.   SEMINARS IN CANCER BIOLOGY

The bone marrow microenvironment and leukemia: biology and therapeutic targeting

(2011) Edward Allan R Sison et al.   Expert Review of Hematology

mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling

(2011) V. S. Rodrik-Outmezguine et al.   Cancer Discovery

Genetic Dissection of the Oncogenic mTOR Pathway Reveals Druggable Addiction to Translational Control via 4EBP-eIF4E

(2010) Andrew C. Hsieh et al.   CANCER CELL

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

(2010) N. Chapuis et al.   CLINICAL CANCER RESEARCH

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

(2010) Matthew R Janes et al.   NATURE MEDICINE

Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy

(2010) C A Sparks et al.   ONCOGENE

Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches

(2009) Marina Konopleva et al.   DRUG RESISTANCE UPDATES

The nuts and bolts of AGC protein kinases

(2009) Laura R. Pearce et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

Functional proteomic profiling of AML predicts response and survival

(2008) S. M. Kornblau et al.   BLOOD

Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML

(2008) Z. Zeng et al.   BLOOD

Mammalian target of rapamycin as a therapeutic target in oncology

(2008) Robert T Abraham et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia

(2008) Weiguo Zhang et al.   JNCI-Journal of the National Cancer Institute

HOX expression patterns identify a common signature for favorable AML

(2008) M Andreeff et al.   LEUKEMIA

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

(2008) A. Y. Choo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA